Phathom Pharma plans public offering after reporting preliminary 2025 results

 

• Phathom Pharmaceuticals (PHAT) said on Wednesday it plans a public offering of common stock and pre-funded warrants, subject to market conditions, shortly after reporting preliminary fourth-quarter and full-year 2025 financial results.
• The drugmaker said it expects fourth-quarter net revenues of about $57 million to $58 million and full-year 2025 revenues of roughly $174.5 million to $175.5 million, based on preliminary unaudited figures. The company reported cash and cash equivalents of about $130 million as of December 31, 2025.
• Phathom said it intends to grant underwriters a 30-day option to purchase up to an additional 15% of the securities offered. The size and terms of the offering have not been disclosed.
• The company said net proceeds from the offering will be used for general corporate purposes, including working capital and commercialization and research and development expenses.

• PHAT -10.93% after hours to $16.05.
• Source: Press Release

https://www.msn.com/en-us/money/companies/phathom-pharma-plans-public-offering-after-reporting-preliminary-2025-results/ar-AA1TLrD7